Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its patented drug candidate Lucid-MS toward Phase 2 clinical trials for multiple sclerosis (MS), according to a recent editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound designed to directly protect the myelin sheath, the protective layer around nerve fibers that is damaged in MS. The company recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and is preparing for a Phase 2 trial following successful completion of Phase 1 safety studies and key toxicology programs.
The editorial highlighted more than a decade of preclinical research supporting Lucid-MS, including studies showing preservation of myelin integrity, reduced degradation, and improved functional recovery in animal models. Quantum BioPharma is also collaborating with Massachusetts General Hospital on validation of a novel PET imaging technique designed to directly measure myelin integrity in MS patients. This tool could help evaluate the effectiveness of remyelinating therapies, including Lucid-MS. The report also noted recent clinical and regulatory developments from Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX), and Bristol Myers Squibb Company (NYSE: BMY), underscoring continued innovation across autoimmune and chronic inflammatory disease treatment markets.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented UNBUZZD(TM) and retains ownership of 19.84% of Unbuzzd Wellness Inc., along with royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity.
For more information, visit the company's newsroom at https://ibn.fm/QNTM.
